Ronellenfitsch Ulrich, Mathis Nika, Friedrichs Juliane, Kleeff Jörg
Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
JMIR Res Protoc. 2022 Apr 28;11(4):e35243. doi: 10.2196/35243.
Lymph node yield is the number of lymph nodes retrieved during oncological resection and histopathologically identified in the resection specimen. It is an important surrogate parameter for assessing the oncological radicality of the resection of gastrointestinal carcinomas, as well as a prognostic factor in these diseases. It remains unclear if and to what extent neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy, which have become established treatments for carcinoma of the esophagus, stomach, and rectum and are increasingly used in pancreatic carcinoma, affect the lymph node yield.
This systematic review with meta-analysis is conducted with the aim of summarizing the available evidence regarding the lymph node yield, an oncological surrogate marker, in patients with gastrointestinal carcinomas undergoing surgery after neoadjuvant therapy compared to those undergoing surgery without neoadjuvant therapy.
Randomized and nonrandomized studies comparing oncological resection of esophageal, stomach, pancreatic, and rectal carcinoma with and without prior neoadjuvant therapy are eligible for inclusion regardless of study design. Publications will be identified with a defined search strategy in 2 electronic databases: PubMed and Cochrane Library. The primary endpoint of the analysis is the number of lymph nodes identified in the resected specimen. Secondary endpoints include the number of harvested metastatic lymph nodes, operation time, postoperative complications, pathological TNM staging, and overall and recurrence-free survival time. Using suitable statistical methods, the endpoints between patients with and without neoadjuvant therapy, as well as in defined subgroups (neoadjuvant chemotherapy, radiotherapy, or chemoradiotherapy; and patients with esophageal, gastric, pancreatic, or rectal cancer), will be compared.
The literature search and data collection started in October 2021. Results are expected to be published in mid-2022.
This meta-analysis will provide the most up-to-date and complete summary of the evidence on an association between neoadjuvant therapy and lymph node yield in gastrointestinal cancer surgery. The underlying hypothesis is that neoadjuvant therapy decreases the number and size of lymph nodes through lymphocyte depletion and radiation-induced fibrosis, thus leading to a lower possible lymph node yield. The findings of the meta-analysis will show if this hypothesis is supported by evidence.
PROSPERO CRD218459; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021218459.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/35243.
淋巴结收获量是指在肿瘤切除术中获取并在切除标本中经组织病理学鉴定的淋巴结数量。它是评估胃肠道癌切除手术肿瘤学根治性的一个重要替代参数,也是这些疾病的一个预后因素。目前尚不清楚已成为食管癌、胃癌和直肠癌既定治疗方法且在胰腺癌中使用越来越多的新辅助化疗、放疗或放化疗是否以及在何种程度上会影响淋巴结收获量。
本系统评价及荟萃分析旨在总结有关接受新辅助治疗后接受手术的胃肠道癌患者与未接受新辅助治疗接受手术的患者相比,作为肿瘤替代标志物的淋巴结收获量的现有证据。
无论研究设计如何,比较有无新辅助治疗的食管癌、胃癌、胰腺癌和直肠癌肿瘤切除术的随机和非随机研究均符合纳入标准。将通过在两个电子数据库(PubMed和Cochrane图书馆)中使用确定的检索策略来识别出版物。分析的主要终点是切除标本中鉴定出的淋巴结数量。次要终点包括收获的转移淋巴结数量、手术时间、术后并发症、病理TNM分期以及总生存时间和无复发生存时间。使用合适的统计方法,将比较接受和未接受新辅助治疗的患者之间以及确定的亚组(新辅助化疗、放疗或放化疗;以及食管癌、胃癌、胰腺癌或直肠癌患者)之间的终点。
文献检索和数据收集于2021年10月开始。结果预计于2022年年中发表。
本荟萃分析将提供关于新辅助治疗与胃肠道癌手术中淋巴结收获量之间关联的最新、最完整的证据总结。潜在假设是新辅助治疗通过淋巴细胞耗竭和辐射诱导的纤维化减少淋巴结的数量和大小,从而导致可能的淋巴结收获量降低。荟萃分析的结果将表明这一假设是否得到证据支持。
PROSPERO CRD218459;https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021218459。
国际注册报告识别号(IRRID):DERR1-10.2196/35243。